PPCH - Propanc Health Group Corporation Mega DD
PPCH Company Description
Propanc Health Group Corporation is a development stage healthcare company whose current focus is the development of new cancer treatments for patients with solid tumors such as pancreatic and colorectal cancer. Propanc, together with its scientific and oncology consultants, has developed a rational, composite formulation of anti-cancer compounds which together exert a number of anti-cancer actions. Propanc's leading products are novel, patented formulations based on proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects, Propanc intends to progress their lead product along the rigorous, formal non-clinical and clinical development pathway required to obtain regulatory approval to market its proenzyme formulation. Propanc intends to undertake development of manufacturing, formal non-clinical studies and then Phase I, II and III clinical trials in order to generate the quality, safety and efficacy data required for regulatory approval. For more information, please visit: http://www.propanc.com
PPCH Products and Services
Propanc Health Group Corporation is a development stage healthcare company whose current focus is the development of new cancer treatments for patients with solid tumors such as pancreatic and colorectal cancer. Propanc was established in 2007 and located in Melbourne, Australia.
Highlights
Targeted therapy for metastatic cancer: Global demand for effective, safe and easy to administer cancer treatments increasing rapidly.
Expansive market demand: Seeking worldwide regulatory approval in several indications, targeting tumor types where few treatment options exist.
Multiple mechanisms of action: Our lead product exerts multiple effects inhibiting tumor growth & blood supply, and stopping it spreading. R&D may identify opportunities for developing new compounds.
Encouraging patient data: 15 years of scientific research and clinical experience suggests our lead product may be an effective treatment against cancer and warrants further development.
Unique intellectual property : Propanc is building an IP portfolio around our scientific understanding of the effects of proenzymes in cancer, new formulations, new routes of
administration and potential new targets
Key Features:
-Global demand for effective, safe and easy to administer cancer treatments is increasing rapidly;
-Propanc seeks worldwide regulatory approval in several therapeutic indications targeting tumor types where a medical need is established and few treatment options exist;
-15 years scientific research and clinical experience from treating patients in the UK & Australia has provided evidence that PRP may be an effective treatment against cancer and warrants further development;
-Propanc is building an IP portfolio around our scientific understanding of the effects of proenzymes in cancer, identifying new formulations, new routes of administration and potential new therapeutic targets.
Future
Propanc’s progressing development of a once-daily proteolytic proenzyme cancer treatment through non-clinical and clinical development, and ultimately, obtaining regulatory approval as an effective, clinically proven therapeutic option. Our intention is to supply this treatment to markets worldwide.
PPCH Key Company Management
James Nathanielsz B.App.Sc, MEI
Executive Chairman
James Nathanielsz has served as a director since inception. Mr. Nathanielsz has served as a director and Chief Executive Officer of our Australian company since October 2007. From July 2006 until October 2007, Mr. Nathanielsz served as the New Products Manager of Biota Holdings Limited, an anti-infective drug development company in Australia. Mr. Nathanielsz was selected as a director because he is the Co-Founder of our Australian company and for his experience in R&D and manufacturing and distribution. Mr. Nathanielsz graduated with a Bachelor of Applied Science, majoring in Biochemistry/Applied Chemistry and subsequently with a Master of Entrepreneurship & Innovation from Swinburne University of Technology in Melbourne, Australia.
http://www.propanc.com/who-we-are/board-of-di...nagers.php
PPCH Contact Info
Propanc Health Group Corporation
James Nathanielsz, Chief Executive Officer
Tel: +61-039208-4182
Email: info@propanc.com
Web: www.propanc.com
PPCH SEC Filings
http://www.otcmarkets.com/stock/PPCH/filings
PPCH Headlines
http://finance.yahoo.com/q/h?s=PPCH+Headlines
Investigate more about PPCH @ http://www.otcmarkets.com/stock/PPCH/quote for more due diligence.
PPCH Company Description
Propanc Health Group Corporation is a development stage healthcare company whose current focus is the development of new cancer treatments for patients with solid tumors such as pancreatic and colorectal cancer. Propanc, together with its scientific and oncology consultants, has developed a rational, composite formulation of anti-cancer compounds which together exert a number of anti-cancer actions. Propanc's leading products are novel, patented formulations based on proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects, Propanc intends to progress their lead product along the rigorous, formal non-clinical and clinical development pathway required to obtain regulatory approval to market its proenzyme formulation. Propanc intends to undertake development of manufacturing, formal non-clinical studies and then Phase I, II and III clinical trials in order to generate the quality, safety and efficacy data required for regulatory approval. For more information, please visit: http://www.propanc.com
PPCH Products and Services
Propanc Health Group Corporation is a development stage healthcare company whose current focus is the development of new cancer treatments for patients with solid tumors such as pancreatic and colorectal cancer. Propanc was established in 2007 and located in Melbourne, Australia.
Highlights
Targeted therapy for metastatic cancer: Global demand for effective, safe and easy to administer cancer treatments increasing rapidly.
Expansive market demand: Seeking worldwide regulatory approval in several indications, targeting tumor types where few treatment options exist.
Multiple mechanisms of action: Our lead product exerts multiple effects inhibiting tumor growth & blood supply, and stopping it spreading. R&D may identify opportunities for developing new compounds.
Encouraging patient data: 15 years of scientific research and clinical experience suggests our lead product may be an effective treatment against cancer and warrants further development.
Unique intellectual property : Propanc is building an IP portfolio around our scientific understanding of the effects of proenzymes in cancer, new formulations, new routes of
administration and potential new targets
Key Features:
-Global demand for effective, safe and easy to administer cancer treatments is increasing rapidly;
-Propanc seeks worldwide regulatory approval in several therapeutic indications targeting tumor types where a medical need is established and few treatment options exist;
-15 years scientific research and clinical experience from treating patients in the UK & Australia has provided evidence that PRP may be an effective treatment against cancer and warrants further development;
-Propanc is building an IP portfolio around our scientific understanding of the effects of proenzymes in cancer, identifying new formulations, new routes of administration and potential new therapeutic targets.
Future
Propanc’s progressing development of a once-daily proteolytic proenzyme cancer treatment through non-clinical and clinical development, and ultimately, obtaining regulatory approval as an effective, clinically proven therapeutic option. Our intention is to supply this treatment to markets worldwide.
PPCH Key Company Management
James Nathanielsz B.App.Sc, MEI
Executive Chairman
James Nathanielsz has served as a director since inception. Mr. Nathanielsz has served as a director and Chief Executive Officer of our Australian company since October 2007. From July 2006 until October 2007, Mr. Nathanielsz served as the New Products Manager of Biota Holdings Limited, an anti-infective drug development company in Australia. Mr. Nathanielsz was selected as a director because he is the Co-Founder of our Australian company and for his experience in R&D and manufacturing and distribution. Mr. Nathanielsz graduated with a Bachelor of Applied Science, majoring in Biochemistry/Applied Chemistry and subsequently with a Master of Entrepreneurship & Innovation from Swinburne University of Technology in Melbourne, Australia.
http://www.propanc.com/who-we-are/board-of-di...nagers.php
PPCH Contact Info
Propanc Health Group Corporation
James Nathanielsz, Chief Executive Officer
Tel: +61-039208-4182
Email: info@propanc.com
Web: www.propanc.com
PPCH SEC Filings
http://www.otcmarkets.com/stock/PPCH/filings
PPCH Headlines
http://finance.yahoo.com/q/h?s=PPCH+Headlines
Investigate more about PPCH @ http://www.otcmarkets.com/stock/PPCH/quote for more due diligence.
